Delta sleep-inducing peptide: what the sleep research shows

Where DSIP came from

In the 1970s, researchers looking for natural substances that promote sleep isolated a small peptide from the blood of sleeping rabbits. They named it delta sleep-inducing peptide because, in early experiments, it appeared to increase delta waves, the slow brain waves of deep sleep. Its official drug name today is emideltide.

At the time, it was one of very few sleep-promoting peptides that had been purified and characterized, which made it an exciting research target.

What the early research found

A 1984 review in Neuroscience and Biobehavioral Reviews summarized the first decade of work. DSIP mainly induced delta sleep in rabbits, rats, mice and humans, though in cats it had a stronger effect on REM sleep. DSIP-like material was found in the brain, other organs and the blood of several mammals.

The review also described a U-shaped response: effects varied with both dose and infusion time, with less effect at both lower and higher amounts. It reported a wide range of other possible effects on hormones, circadian rhythms, behavior and drug withdrawal. A substance that seems to do many things in early studies often turns out to do none of them reliably in controlled trials.

Why the human evidence is weak

Human studies of DSIP were mainly conducted in the 1980s and early 1990s. They were small, used different doses and routes, and did not consistently show better sleep. There are no large, modern, placebo-controlled trials in adults with insomnia, and none in midlife adults specifically.

Even the basic biology remains uncertain. Researchers never clearly identified a specific receptor for DSIP or a gene that encodes it, which makes it hard to understand how it would work or predict its effects.

What FDA reviewers said in 2026

When the FDA's Pharmacy Compounding Advisory Committee reviewed emideltide in July 2026 for chronic insomnia, narcolepsy and opioid withdrawal, FDA staff said there was a lack of safety and efficacy data for those uses. They also raised concerns that the ingredient is not adequately characterized and may contain impurities from peptide manufacturing. The FDA's safety-risk listing has noted possible immune reactions and no safety information for the proposed route.

The committee voted 6 to 7, with one abstention, against recommending DSIP for the compounding list. The vote is non-binding and the FDA has not taken final action. DSIP is not FDA-approved.

Why sleep studies are hard to read

Sleep is especially prone to placebo effects. In many insomnia trials, people taking a dummy pill report sleeping noticeably better, partly because expectations and simply paying attention to sleep habits change behavior. Without a placebo group, an improvement after starting any sleep product is very hard to interpret.

Sleep also varies a lot from week to week, and people usually seek help when it is at its worst, so some improvement is likely regardless of what they try. That is why the small, uncontrolled DSIP studies of past decades cannot settle the question, and why any personal trial should include a sleep diary started before the first dose.

Treatments with stronger evidence

The National Heart, Lung, and Blood Institute recommends cognitive behavioral therapy for insomnia (CBT-I) as the usual first treatment for long-term insomnia. It runs 6 to 8 weeks and can be done online. Several FDA-approved prescription medicines are available when CBT-I is not enough, each with known benefits and risks.

In midlife, poor sleep often has a specific cause. Sleep apnea, night sweats from perimenopause, alcohol, chronic pain, low mood, an overactive bladder and medicines can all fragment sleep. Treating the cause usually helps far more than any sleep aid.

• Keep consistent sleep and wake times, including weekends
• Keep the bedroom cool, dark and quiet, and put screens away before bed
• Avoid caffeine, nicotine and alcohol close to bedtime
• Exercise during the day, finishing several hours before bed
• Ask your clinician whether any of your medicines disturb sleep

If you still want to discuss DSIP

Your HealifyMD clinician starts with a sleep-focused assessment, including screening for sleep apnea and hormone-related sleep changes. If DSIP is considered after that, it is framed as a short, closely monitored trial with a sleep diary before and after, and a clear point to stop if it does not help. It is offered only if a licensed U.S. pharmacy confirms it can lawfully dispense it.

DSIP is a compounded preparation, not FDA-approved and not reviewed by the FDA for safety, effectiveness or quality. The listed price starts at $200/month, or $350 for two months ($175/month), with no membership fee, confirmed at the eligibility review. We do not publish home dosing instructions.